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The consensus guideline reported in 2012 by Palladini G et al outlines a set of criteria for organ and hematological response to treatment for AL amyloidosis that prognosticate patient outcomes. 2 The paper highlights the importance of timely assessment of patients' responses to treatment using these prognostic markers to guide therapeutic decisions. As our understanding and treatment approaches for AL amyloidosis evolve, there is continued research into developing sensitive and accurate markers that can measure treatment efficacy and can reliably predict patient survival outcomes.
In the field of multiple myeloma, the clinical utilities of multiparameter flow cytometry (MFC), Ig allele-specific oligonucleotide-based quantitative PCR, and next-generation sequencing of Ig genes have been an area of extensive research. 3 These methods have been tested for diagnosis, immunophenotyping and assessment of minimal residual disease (MRD) in multiple myeloma patients. Studies have shown that persistence of MRD in the bone marrow after treatment predicts poor PFS and overall survival in multiple myeloma patients. [3] [4] [5] [6] [7] Given their clinical utility, immunophenotyping and MRD assessment have become a part of a routine laboratory assessment of patients with multiple myeloma in current clinical practice. 3 The use of MFC and MRD assessment in AL amyloid patients is an emerging area of interest. Several studies have started to investigate the role of MFC in the assessment of AL amyloidosis patients and patient outcomes. [8] [9] [10] The purpose of our study is to discuss the feasibility of MRD assessment using MFC in a cohort of five patients with AL amyloidosis treated at our center.
All consecutive patients who underwent single auto-SCT at Tom Baker Cancer Center (TBCC) from January 2010 to December 2015 using Bor-HDM were evaluated. The diagnosis of AL amyloidosis and assessment of hematological and organ response were performed based on the consensus criteria published in 2005 and modified in 2012. 2 MRD was assessed by multiparameter flow cytometry as per Euroflow consensus guidelines.
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All but one patient received a median of two cycles of induction chemotherapy before undergoing auto-SCT (Cyclophosphamide, Bortezomib and Dexamethasone, 'CyBorD'). Bortezomib was administered IV at 1-1.3 mg/m 2 on days − 5, − 2, 1 and 4, while melphalan was given at 200 mg/m 2 on day − 1. The study analyzed the data from five patients with diagnosis of AL amyloidosis who were treated with auto-SCT. The median age was 60 years (range 56-62). The clinical characteristics of the patient group are outlined in Table 1 . Treatment and hematological responses are summarized in Table 2 . After induction chemotherapy with CyBorD, ⩾ VGPR was seen in one of the five patients. At day-100 post auto-SCT, four patients had ⩾ VGPR (80%). Complete response was found in two patients, and both of these patients were found to have MRD negativity by MFC analysis. The three patients who did not achieve CR post auto-SCT went on the receive consolidation therapy with CyBorD.
All five of the patients had an organ response at a median of 6 months post ASCT. The two patients who achieved CR developed oligoclonal diseases after ASCT. At the time of analysis, all patients are alive and progression free with a median follow-up of 18 months. Time to engraftment and length of hospitalization was similar to that reported for our historical cases. In regards to toxicity, three patients developed moderate-to-severe diarrhea and one patient tested positive for C.difficile infection and was treated successfully. In addition, one patient developed an episode of rash that required prednisone treatment.
The diagnosis of AL amyloidosis requires evidence of tissue deposits of amyloid protein. In addition, the diagnosis requires evidence of plasma cell dyscrasia through a bone marrow biopsy showing clonal plasma cells (PCs) producing monoclonal light chains, or by detection of abnormal monoclonal light-chain ratio in the serum or urine. 1 Previous reports have described the technical challenges in identifying abnormal cells in the bone marrow by morphology alone. Due to the small clonality and minimal morphological aberrations of the abnormal PCs, it is difficult to discern their presence among the normal PCs in the bone marrow biopsies. 8 MFC allows for the identification of abnormal cells by using multiple parameters, including both intracellular and cell surface markers to characterize individual PCs. It is able to sort through a large volume of samples in a timely manner. 12 MFC has been tested by several studies in the diagnosis and characterization of AL amyloidosis. In the study by Paiva B et al. 10 in 2011, MFC immunophenotyping was shown to be a highly sensitive means to detect PC clonality in the bone marrow (97% sensitivity), and the study suggested that it may be diagnostically useful for identification of the type of amyloidosis when tissue staining is postive for amyloid. Comparable detection sensitivity was seen by Lisenko, K., et al. who found 97% sensitivity in detection of abnormal PC clones using MFC analysis of bone marrow samples of 63 AL amyloid patients. It is interesting to note that in their analysis, MFC detected amyloidogenic clones that were not specified by immunohistochemistry or bone marrow biopsy. Their paper also reported that MFC was able to discern the difference between malignant PCs versus B cells, as well as to identify specific cell markers that may guide potential targetted therapy. 9 In additon to its diagnostic use, MFC has also been employed to yield information that has prognostic value in AL amyloidosis. MFC has been tested in AL amyloidosis to identify specific measurements and immunophenotypic makers that showed association with patient outcomes. Paiva, B et al. reported that patients who had a monoclonal bone marrow PC (BMPC) percentage of 41% by MFC immunophenotyping had a poorer overall survival compared to patients with BMPC percentage o1%.
10 Furthermore, Baginska A et al. 13 reported a cohort of 48 AL amyloid patients, where detection of 45% of normal immunophenotypic PCs (CD38+CD138+CD19+) was associated with better survival. They also described that CD56 expression was associated with cardiac involvement. In addition, CD27 expression was associated with worse degree of hematological response and overall survival. Patients with abnormal PCs that expressed both CD56 and CD27 had poorer progosis with median survival of 2 months. As these studies have discussed, MFC analysis is useful not only in detecting the presence or absence of PCs in AL amyloidosis but also in characterizing the specific immunological phenotype of the cells, allowing for potential targetted approach to therapy.
Most recently, Muchtar E et al. reported results from MFC analysis of bone marrow at time of diagnosis and at the end of first-line treatment in 173 AL amyloid patients. In the subpopulation of patients who did not undergo autologous stem cell transplantation (ASCT) percentage of monotypic PCs 42.5% at time of diagnosis was associated with poorer PFS and overall survival (OS). Polytypic PCs/ bone marrow PC ratio of o 5% was also related to worse PFS and OS. Interestingly, these percentage markers did not show relevance to outcomes in patients who underwent ASCT. MFC analysis at the end of treatment showed that in the cohort of cases with better than VGPR, less than 0.1% of monotypic PC was associated with better PFS and OS. 14 The paper highlighted that MFC analysis may be useful both at the time of diagnosis and after treatment completion to generate information that will help in prognostication of patient survival.
The role of MFC for immunophenotyping and MRD assessment in understanding AL amyloidosis is at its early stages. Our study is one of the first to explore the role of MFC in the MRD assessment of AL amyloid patients undergoing ASCT. A recent abstract published by Palladini G et al. also reported results of MRD assessment in 17 of their AL amyloidosis patients, and found that nearly half of the patients with CR had MRD positivity. 15 As discussed above, recent studies in AL amyloidosis are starting to highlight the use for MFC as an effective tool that can guide our understanding and treatment of AL amyloidosis. With the advent of novel and efficacious treatment approaches such as ASCT and Bor-HDM conditioning regimens, tools such as MRD by MFC will help us assess deeper responses. Further studies with larger patient numbers are required to validate these early results and the possible implications for long term survival. Consolidation response ⩾ VGPR 100%
Abbreviations: MRD = minimal residual disease; SCT = stem cell transplantation.
